A recent study indicates that patients who stop using new weight-loss injections like semaglutide or tirzepatide tend to recover shed pounds at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a leading medical journal points out that while obese individuals can lose a large proportion of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying these drugs should be aware of the danger of fast rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
That rate of regain means a reversion to original mass in about 18 months.
Comparing Treatments
The research, which examined 37 of trials involving thousands of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers note that people who shed pounds through diet and exercise typically see a less rapid creep back—approximately 100 grams monthly—after stopping.
The Reason for the Quick Regain
Doctors propose the mechanism of the jabs explains the amplified weight return.
The injections mimic a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing the hormone levels several times higher than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making overeating far more likely."
A Chronic Condition?
Medical guidelines suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals say that, due to the significant potential of weight regain, the treatment is often life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," comparing it to managing conditions like diabetes.
Patient Accounts
People who have discontinued the jabs explain a intense return of appetite.
"It was like a trigger flipping and you're instantly extremely hungry," described a patient.
The struggle is worsened if patients have not adopted sustainable lifestyle or habit changes during treatment.
Growing Use
Figures suggest that millions of people in the UK have used these injections in the past year, with desire continuing to grow.
- Adoption is greater among women compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
In conclusion, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a magic solution and long-term success likely depends on integrated lifestyle support.
